Actavis Files Application for Generic Version of Safyral, Is Sued by Bayer

Actavis Inc. June 5 confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration for a generic version of Bayer’s birth control drug Safyral.

Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) is indicated to prevent pregnancy in women who elect to use an oral contraceptive, and to provide a daily dose of folate supplementation.

Merck & Co., Bayer Pharma AG, and Bayer Healthcare Pharmaceuticals Inc. filed suit against Actavis June 4 in the U.S. District Court of Delaware, seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of ...